Persista Bio Inc
Persista Bio® enables the promise of cellular biotherapeutics with long-term implants that mimic the body’s processes. The O2Line™ technology is an oxygenated, macroencapsulation system for delivering and maintaining allogeneic therapeutic cell implants. Two features of the system include a unique anti-fibrotic cell capsule and an in-situ oxygen generator to support the membrane encapsulated cells. The product will be fully implantable with no need for immunosuppression. Initial preclinical data is in the treatment of Type 1 diabetes. The O2Line™ system will enable the major advancements in stem cell biology to become long-term, curative cell therapy treatments for chronic diseases including metabolic diseases.
Persista Bio is a seed stage company located in Ithaca NY. Persista Bio’s co-founders are inventors on a series of key technologies licensed from Cornell University and Giner, Inc. Two co-founders, Dr. Linda Tempelman and Dr. Minglin Ma, are experienced entrepreneurs.
